Earnings Call · Q2 FY2024·2024-08-13

Q2 24EPS +50.00%·Rev n/aQ1 24EPS -15.69%·Rev n/aQ4 23EPS +17.39%·Rev n/aQ3 23EPS +5.88%·Rev n/a⚠ consensus missing

BioRestorative Therapies, Inc. BRTX

Stephen Kilmer — Investor Relations

Lance Alstodt — Chief Executive Officer

Robert Kristal — Chief Financial Officer

Francisco Silva — Chief Scientific Officer

−0.7%1d on move date−1.0% vs SPY3d+12.8%5d+18.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more BRTX calls or request research access.

More BRTX calls Browse calls Request research access